Correlación de sobrepeso y obesidad con la presión arterial en adultos mayores en una unidad de primer nivel en Tabasco

Objetivo. Determinar la prevalencia de sobrepeso y obesidad en adultos mayores en la Unidad de Medicina Familiar (UMF) del Instituto de Seguridad Social del Estado de Tabasco (ISSET) y su correlación con la presión arterial. Material y métodos: Se realizó un estudio observacional, retrospectivo, analítico, transversal en 7322 adultos de 60 años o más. Se obtuvieron las mediciones de peso, talla, presiones arteriales sistólica, diastólica y media, además de diagnósticos registrados en los expedientes clínicos. Se utilizaron estadísticas descriptivas de tendencia central y se calculó el coefiiente de correlación de Pearson (r) para el índice de masa corporal con las mediciones de presión arterial y se consideraron signifiativas aquellas con una

Cardiovascular disease in women: Do we need new diagnostic and therapeutic strategies?

Cardiovascular disease (CVD) is the leading cause of death worldwide affecting both genders equally. However, in comparison to men, in women it often is underrecognized and undertreated in both the primary and secondary prevention settings. It is clear, that in the healthy population, there are profound differences both anatomically and biochemically between woman and men and this may impact how both groups present when they become ill. Therefore, there are some diseases that affect more frequently in women than in men such us myocardial ischemia or infarction without obstructive coronary disease, Tako-subo syndrome, some atrial arrhythmias or the appearance of heart failure with preserved ejection fraction. Therefore, the diagnostic and therapeutic strategies that have been established based largely on clinical studies with a predominant male population must be adapted before being applied to women. There is a paucity of data regarding cardiovascular disease in women. It is inadequate to only perform a subgroup analysis evaluating a specific treatment or invasive technique, when women constitute fifty percent of the population. In this regard, this may affect the time of clinical diagnosis and severity assessments of some valvulopathies. In this review, we will focus on the differences in the diagnosis, management, and outcomes of woman with the most frequent cardiovascular pathologies including coronary artery disease, arrythmias, heart failure and valvopathies. In addition, we will describe diseases that exclusively affect to women related with the pregnancy some of them are life treating. Although the lack of research in women plays a role in the poorer outcomes in women specially in ischemic heart disease the results of some techniques such as transcathether aortic valve implantation and transcatheter edge to edge therapy seem to have better outcome in women

Tratamiento percutáneo de insuficiencia mitral severa por rotura de neocuerdas

Percutaneous mitral valve repair techniques have raised substantial interest in recent years, because they allow treating serious lesions avoiding surgical complications with good results in well-selected patients. Echocardiography is absolutely essential in the transcatheter mitral repair procedure and in the selection of candidates for this technique. We present a clinical case of percutaneous edge-to-edge mitral repair treatment in a patient with recurrence of severe mitral regurgitation after having previously undergone neochordal implantation, in which echocardiography played an essential role.Las técnicas de reparación mitral percutánea han generado mucho interés en los últimos años ya que permiten tratar lesiones graves evitando las complicaciones quirúrgicas y con buenos resultados en pacientes bien seleccionados. La ecocardiografía es completamente imprescindible en la reparación mitral transcatéter y en la selección de pacientes candidatos a esta técnica. Presentamos un caso clínico de tratamiento percutáneo de reparación mitral borde a borde en una paciente con recurrencia de insuficiencia mitral grave tras haber sido previamente intervenida con el implante de neocuerdas en el que rol de la ecocardiografía fue esencial

Informe de la asistencia bucodental en el servicio de odontología de la villa paralímpica durante los IX Juegos Paralímpicos de Barcelona '92

Durante los Juegos Paralímpicos se dispuso de un servicio de Odontología para atender cualquier problema urgente bucodental que se les pudiera presentar a los integrantes de la 'familia paralímpica'. Se hace hincapié en los motivos por los que acudieron al servicio y se quiere llamar la atención sobre el mal estado bucodental de los deportistas

El labrador: Año I Número 3 - (14/03/22)

BACKGROUND: Use of everolimus-eluting stents (EES) has proven to be clinically effective and safe in patients with ST-segment elevation myocardial infarction but it remains unclear whether it is cost-effective compared to bare-metal stents (BMS) in the long-term. We sought to assess the cost-effectiveness of EES versus BMS based on the 5-year results of the EXAMINATION trial, from a Spanish health service perspective. METHODS: Decision analysis of the use of EES versus BMS was based on the patient-level clinical outcome data of the EXAMINATION trial. The analysis adopted a lifelong time horizon, assuming that long-term survival was independent of the initial treatment strategy after the end of follow-up. Life-expectancy, health-state utility scores and unit costs were extracted from published literature and publicly available sources. Non-parametric bootstrapping was combined with probabilistic sensitivity analysis to co-assess the impact of patient-level variation and parameter uncertainty. The main outcomes were total costs and quality-adjusted life-years. The incremental cost-effectiveness ratio was expressed as cost per quality-adjusted life-years gained. Costs and effects were discounted at 3%. RESULTS: The model predicted an average survival time in patients receiving EES and BMS of 10.52 and 10.38 undiscounted years, respectively. Over the life-long time horizon, the EES strategy was €430 more costly than BMS (€8,305 vs. €7,874), but went along with incremental gains of 0.10 quality-adjusted life-years. This resulted in an average incremental cost-effectiveness ratio over all simulations of €3,948 per quality-adjusted life-years gained and was below a willingness-to-pay threshold of €25,000 per quality-adjusted life-years gained in 86.9% of simulation runs. CONCLUSIONS: Despite higher total costs relative to BMS, EES appeared to be a cost-effective therapy for ST-segment elevation myocardial infarction patients due to their incremental effectiveness. Predicted incremental cost-effectiveness ratios were below generally acceptable threshold values

Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial.

BACKGROUND: Use of everolimus-eluting stents (EES) has proven to be clinically effective and safe in patients with ST-segment elevation myocardial infarction but it remains unclear whether it is cost-effective compared to bare-metal stents (BMS) in the long-term. We sought to assess the cost-effectiveness of EES versus BMS based on the 5-year results of the EXAMINATION trial, from a Spanish health service perspective. METHODS: Decision analysis of the use of EES versus BMS was based on the patient-level clinical outcome data of the EXAMINATION trial. The analysis adopted a lifelong time horizon, assuming that long-term survival was independent of the initial treatment strategy after the end of follow-up. Life-expectancy, health-state utility scores and unit costs were extracted from published literature and publicly available sources. Non-parametric bootstrapping was combined with probabilistic sensitivity analysis to co-assess the impact of patient-level variation and parameter uncertainty. The main outcomes were total costs and quality-adjusted life-years. The incremental cost-effectiveness ratio was expressed as cost per quality-adjusted life-years gained. Costs and effects were discounted at 3%. RESULTS: The model predicted an average survival time in patients receiving EES and BMS of 10.52 and 10.38 undiscounted years, respectively. Over the life-long time horizon, the EES strategy was ¿430 more costly than BMS (¿8,305 vs. ¿7,874), but went along with incremental gains of 0.10 quality-adjusted life-years. This resulted in an average incremental cost-effectiveness ratio over all simulations of ¿3,948 per quality-adjusted life-years gained and was below a willingness-to-pay threshold of ¿25,000 per quality-adjusted life-years gained in 86.9% of simulation runs. CONCLUSIONS: Despite higher total costs relative to BMS, EES appeared to be a cost-effective therapy for ST-segment elevation myocardial infarction patients due to their incremental effectiveness. Predicted incremental cost-effectiveness ratios were below generally acceptable threshold values

Eco-fusión. Aplicación en el intervencionismo estructural cardíaco

The evolution in percutaneous structural intervention has generated a parallel development in advanced imaging techniques. Echocardiography plays a key role in structural intervention in patient selection, assessment during the fluoroscopy and immediate analysis of outcomes and early detection of complications; echo-fusion images appear as a complementary tool in which two techniques with dynamic images are complemented in a single image in order to guide, decrease intervention time and reduce complications.La evolución en el intervencionismo estructural percutáneo ha generado un desarrollo paralelo en las técnicas de imagen avanzada. La ecocardiografía en el intervencionismo estructural juega un papel básico en la selección de los pacientes, en la valoración durante el procedimiento y en el análisis inmediato de los resultados y la detección precoz de complicaciones. Las imágenes de fusión eco/fluoroscopia aparecen como una herramienta complementaria en la que dos técnicas con imágenes dinámicas se complementan en una sola imagen con el fin de orientar, disminuir el tiempo de intervención y disminuir las complicaciones

Successful development and clinical translation of a novel anterior lamellar artificial cornea

We thank the Andalusian Public Foundation Progress and Health, through the Andalusian Initiative for Advanced Therapies, for assuming the roles and responsibilities of sponsoring this clinical trial. We thank Dr. Manuel de la Rosa and Dr. Salvador Arias Santiago for providing insight and expertise that assisted the research.The datasets generated and/or analyzed during the current study are available in the Gene Expression Omnibus (GEO) public repository, ref. GSE86584 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86584Blindness due to corneal diseases is a common pathology affecting up to 23 million individuals worldwide. The tissue‐engineered anterior human cornea, which is currently being tested in a Phase I/II clinical trial to treat severe corneal trophic ulcers with preliminary good feasibility and safety results. This bioartificial cornea is based on a nanostructured fibrin–agarose biomaterial containing human allogeneic stromal keratocytes and cornea epithelial cells, mimicking the human native anterior cornea in terms of optical, mechanical, and biological behavior. This product is manufactured as a clinical‐grade tissue engineering product, fulfilling European requirements and regulations. The clinical translation process included several phases: an initial in vitro and in vivo preclinical research plan, including preclinical advice from the Spanish Medicines Agency followed by additional preclinical development, the adaptation of the biofabrication protocols to a good manufacturing practice manufacturing process, including all quality controls required, and the design of an advanced therapy clinical trial. The experimental development and successful translation of advanced therapy medicinal products for clinical application has to overcome many obstacles, especially when undertaken by academia or SMEs. We expect that our experience and research strategy may help future researchers to efficiently transfer their preclinical results into the clinical settings.This study was supported by the Spanish National Plan for Scientific and Technical Research and Innovation (I + D + I) from the Spanish Ministry of Economy and Competitiveness (Carlos III Institute of Health), grants FIS PI14/0955 and FIS PI17/0391 (both cofinanced by ERDF‐FEDER, European Union); by the Spanish Ministry of Health, Social Policy and Equity, grant EC10‐285; and by preclinical research funds from the Regional Ministry of Health through the Andalusian Initiative for Advanced Therapies